Thomson200 / Wikimedia Commons (CC0)The Third Reading
Battery Power says 'disastrous.' Anthopoulos says 'got better.' The deGrom no-trade clause and the price tag on Drake Baldwin tell a story neither side wants to acknowledge.
Eight games. That is the distance between the Atlanta Braves and the second-place Phillies in the National League East. The Braves are 67-45, riding a five-game winning streak, in possession of the best bullpen in baseball. Battery Power looked at the trade deadline and called it "disastrous."
Alex Anthopoulos looked at the same deadline and said his team "got better."
Both positions contain data. Neither contains the whole picture.
The word "disastrous" carries a specific charge -- negligence, a failure of ambition, a front office that stared at October and blinked. Anthopoulos's rebuttal was measured and, unusually, specific. He cited the rotation's fifth-best ERA in baseball since the All-Star Break and named the cost of the alternative: "Drake Baldwin would have been going out the door."
General managers do not identify their own franchise players as trade currency on the record. Anthopoulos did. The market priced an elite starter above the reigning Rookie of the Year, and he refused to pay.
Then there is Jacob deGrom. The two-time Cy Young winner invoked his no-trade clause to block a deal with Atlanta -- not because of Atlanta specifically, but because deGrom declined all suitors. "I want to be here," he told reporters in Arlington. "I believe in this group." The distinction reshapes the narrative entirely. Battery Power's grade assumes the Braves chose restraint. The deGrom clause reveals something else: the Braves reached for the big arm. The big arm said no.
I analyzed the individual trades yesterday. I will not relitigate the details. The question this morning is not what the Braves acquired. It is whether what they acquired, combined with what they already had, constitutes an October roster.
The case for sufficiency is the bullpen. Dylan Lee, Robert Suarez, and Raisel Iglesias have combined for a 1.43 ERA and a .184 opponent batting average across 107.1 innings this season. The unit's ERA- of 65 since May 18 is the best mark in baseball, confirmed by a top-five FIP- of 85 -- meaning the performance is structural, not lucky. In a postseason built around shortened games and compressed leverage, this is not a peripheral advantage. It is the argument.
The case for concern is the rotation behind Chris Sale. Sale's 2.06 ERA is the third-lowest in the majors and the third-lowest by a pitcher 37 or older since 1950. He is, by any honest measure, the best pitcher in either league right now. But October is a rotation, not a single arm, and the men behind Sale -- Strider done for the year, Lopez on the injured list with no firm return date -- leave a projected playoff rotation of Sale, Elder, Holmes, Mahle, and Perez. One proven postseason arm and four pitchers who have never started a playoff game.
Anthopoulos cited that fifth-best rotation ERA since the All-Star Break as his defense. The stat is real. The sample is roughly three weeks -- long enough to encourage, short enough to mislead.
Meanwhile, the Phillies reorganized their entire infield to accommodate Luis Arraez -- the three-time batting champion hitting .324 -- moving Stott to third, Bohm to first, Harper to right field. They did not add a piece to their puzzle. They redesigned the puzzle. And while Philadelphia built up, the Mets tore down -- seven deals, eight MLB players shipped out -- softening the division's bottom half while the top grew sharper.
Ten days ago I asked why seventy-seven percent of The Athletic's staff picked the Phillies despite the Braves leading by six. The question has a different texture now. The Phillies added a batting champion. The Braves added a reclamation starter and a platoon bat. The standings say eight games. October readiness is harder to count.
The honest reading is this: the Braves tried for more and the market refused. Anthopoulos drew a line at Baldwin -- a defensible line, possibly the correct one -- and the consequence is a roster that must win in October with Sale, a bullpen, and whatever the word "enough" turns out to mean. The Braves have been betting on depth since March. The deadline did not change the bet. It clarified the stakes.
The Tilt
The Braves are betting that the best bullpen in baseball can turn a five-man rotation question into a three-pitcher answer in October.
— Ellis Magnolia
What's your take?
Ellis Magnolia
Numbers & narrative — statistical depth worn lightly, literary pacing.
Keep Reading

deGrom Said No
The Braves pursued deGrom for two weeks and got rejected. Atlanta's deadline failure just went from passive to personal.
Chris Sale Can't Pitch Game 2
ESPN called the Braves the deadline's biggest losers. They're right about the verdict. They're wrong about the crime scene -- it happened in Los Angeles.
_(51101555196).png&w=3840&q=75)
Seven Starts
The Braves spent the deadline acquiring a recency bet on Tyler Mahle and a platoon upgrade in Lane Thomas. With Reynaldo Lopez's knee on the IL and Spencer Strider likely done for the year, the question is not whether these moves are correct -- it is whether correct is enough.